Antibiotics have greatly reduced the morbidity and mortality due to infectious diseases. Although 29 antibiotic resistance is not a new problem, its breadth now constitutes a significant threat to human 30 health. One strategy to help combat resistance is to find novel ways to use existing drugs, even those 31 that display high rates of resistance. For the pathogens Escherichia coli and Pseudomonas aeruginosa, 32 pairs of antibiotics have been identified for which evolution of resistance to drug A increases sensitivity 33 to drug B and vice versa. These research groups have proposed cycling such pairs to treat infections, 34 similar treatment strategies are being investigated for various cancer forms as well. 35
48

INTRODUCTION 50
The impending era of ubiquitous antibiotic resistance is engendering an urgent search for new 51 therapeutics as well as antibiotic stewardship strategies. Clinical strains have recently been isolated that 52 are completely pan resistant -resistant to all available antibiotics. In lieu of new drugs or vaccines, 53 optimizing therapeutic regimen is critical to continued treatment success. Stewardship approaches 54 incorporating such considerations would ideally reduce the risk of within-host resistance development 55 thus minimizing endemic levels of such strains in the community. 56
The concept of collateral sensitivity (CS) was described already in the 1950s, when Bryson et al. 57 observed that an Escherichia coli strain became hypersensitive to polymyxin B, upon acquiring 58 chloramphenicol resistance. 1 They speculated that this collateral sensitivity could be exploited clinically. 59
Recently, research teams have identified drug pairs that exhibit mutual collateral sensitivity (MCS) 60 effects; evolution of resistance to drug A increases sensitivity to drug B and vice versa. MCS entails a 61 reciprocal positive interaction between the two drugs. For the pathogens Escherichia coli and 62
Pseudomonas aeruginosa, a number of pairs of antibiotics have been identified which exhibit MCS to 63 varying degrees. [2] [3] [4] [5] Based on these studies, several groups have proposed antibiotic cycling of two 64 antibiotics (e.g., A -> B -> A -> B -> ..., and derivatives thereof) to exploit MCS and to treat infections. 2 65 However, all, except one study were limited to a single exposure to each antibiotic. While recent work 66 has provided some understanding and potential mechanistic causes of such evolved sensitivity, it is 67 unclear if CS is a universally applicable treatment consideration. 68
For P. aeruginosa infections in prophylactically exposed cystic fibrosis, CF, patients, i) gentamicin 69 resistant strains are seen to become sensitive to penicillin due to mutation in a two component system 70 (pmrB), and, ii) nalC and mexZ mutations can confer aminoglycoside sensitivity in beta-lactam adapted 71 strains. 4 Data emerging from whole genome sequencing of such isolates points to the need for a 72 thorough exploration of the pharmacodynamic features of such treatment regimen where the CS 73 strategy is employed. Roemhild et al cycled two antibiotics at a time in a morbidostat, an in vitro 74 continuous-flow model. 6 The morbidostat maintains a population density below a desired threshold by 75 administration of bolus doses of antibiotic at specified optical densities. While a clever and useful device 76 amenable to control and automation, for the potential clinical application, it trivializes the 77 pharmacodynamics and greatly simplifies the underlying modeling. In this case, their model shows rapid 78 ascent of double mutants and experimentally, they find this in most cases. In addition to this, Nichol et 79 al recently presented a combinatorial model describing the evolutionary limitations of CS strategy 80 focusing on drugs with the same molecular target; cell wall synthesis. 7 They concluded that 'collateral 81 sensitivity is contingent on the repeatability of evolution'. 82
Theoretical models can guide the testing and implementation of this cycling strategy, in light of the 83 evolutionary trends towards amplification of resistant clones during sequential monotherapies. Using 84 simulated treatment protocols, the plausibility of CS-derived treatment regimen can be evaluated in 85 silico and optimized in vivo. In this way, the implications for resistance development and the endemic 86 fixation of these alleles can be assessed in 'real time' before in vivo testing. 87
In this manuscript, we analyze the population dynamics of antibiotic cycling with the goal of clinical 89 utility. We utilize clinically relevant parameters for presenting infections; high bacteria densities and 90 antibiotic dosages in line with current treatment protocols. 8 Such models combined with PK / PD 91 experiments would guide the clinical applicability of this proposed new treatment paradigm. Our model 92 explicitly incorporates PD / PK parameters for individual strains, their mutation rates and bacterial 93 fitness effects. Implicit within our model is immune control of bacterial density. We examine the 94 sequential application of two drugs, A → B, each exhibiting different PD characteristics, to a hypothetical 95 infection and estimate the rates of resistance ascent or population decline for single and multiply 96 resistant clones in the simulated patient. The simulation results provide a foundation for validating this 97 treatment framework. Time to clearance (of a hypothetical bacterial infection) represents the positive 98 end of the scale, and time to fixation, Tfix, the negative end which the study focuses on for convenience. 99
The presented framework is well-grounded in the underlying ecological, evolutionary, and 100 pharmacological theory driving collateral sensitivity, and allows us to study the efficacy of treatment 101 achievable under such regimen. 102
103 Current examples and proposals of MCS are for two drug cycling and we formulated our original model 104 to study this. It is not only applicable to antimicrobial chemotherapy but also to cancer chemotherapy 105 where investigators have been studying treatment strategies of various cancers based on MCS 106 considerations, although with mixed experimental results. 9 107 108 109
MATERIAL AND METHODS 110
We construct a compartment model where a susceptible population of bacteria, S, is exposed 111 successively to two antimicrobial drugs, A1 and A2, and simulate treatment over a period of 10 days in 112 most cases, and longer where necessary. All strains compete for a limited nutrient and grow at their 113 respective maximum rates in the absence of antibiotic pressure. Resistance confers a fitness 114 disadvantage of 10% for singly resistant mutants with a multiplicative factor of 10% per additional 115 resistance mutation(s). The pharmacokinetics are provided by equations relevant to an in vitro kinetic 116 model or chemostat 10 at a rate mimicking human glomerular filtration (GFR). The at times neglected 117 pharmacodynamics is incorporated by modulating minimum growth rates relative to each strain's 118 respective MIC, as opposed to by the MIC alone. Collateral sensitivity is accounted for by switching the 119 MIC of the relevant (pre-exposed) strain at periods corresponding to when the antibiotic is cycled and CS 120 is assumed to be instantaneous. A flow diagram representing the model is presented in Figure 1 . Our treatment protocol consists of exposing a sensitive population of N0 = 2 x 10 8 CFU ml -1 of bacteria to 130 each antibiotic as described below. We set the flow rate to 0.2 l h -1 and assume a basal mutation rate, µ, 131 of 3.9 x 10 -10 nucleotide -1 generation -1 , a conservative estimate as compared to the estimated range of µ. 132 11 A single mutation is assumed to be sufficient to induce clinically significant resistance and that there is 133 an insignificant likelihood of reversion to full sensitivity. 12 134
For sensitive cells, the MIC is set to 1 µg ml -1 . When applying drug A or drug B, the MIC of the cells 135 resistant to drug B or drug A respectively, is set to 0.5 µg ml -1 and the cells are thus more sensitive than 136 the sensitive cell population. The MIC of resistant cells is always set at 16 µg ml -1 prior to switching 137 when antibiotic is cycled. We assume a 10% reduction in fitness by imposing a penalty on maximum growth rate. For each resistance 'acquisition' an additive fitness penalty is incurred with the triply 139 resistant isolate being least 'fit'. 140 141 Antibiotics are pulsed at concentration, C µg ml -1 (3 ≤ c ≤ 10) into the chemostat for one hour, followed 142 by 5 hours of medium alone. This is repeated four times per day and the antibiotic is switched daily 143 (Pharma7d, 6h). The pharmacodynamic responsiveness of the exposed population to antibiotic 144 concentration is reflected in the Hill coefficient, , which defines how 'rapidly' the maximum efficacy is 145 attained; the sensitivity of the bacterial population at concentrations close to the MIC. 146
We simulate MCS-guided treatment with daily, and 3 day cycling between antibiotics. 147
We follow each population throughout the treatment period and estimate time to clearance or the time 148 to fixation of multiple drug resistance for either 2 or 3 drug rotations. The inhibitory effect of each 149 antibiotic is reflected in the term, , which also reflects the maximal kill rate for each antibiotic. 150
Values for and are derived from experimental studies on Escherichia coli and Staphylococcus 151 aureus. 13, 14 We model the intrinsic growth of the population using a Monod model with resource 152 conversion efficiency, e = 5 x 10 -7 µg, and a Monod constant, к of 0.25 µg ml -1 (See Levin et. al, 1977 15 ). 153
Initially, there are no resistant isolates and we assume that the bacteria do not engage in horizontal 154 gene transfer, a critical assumption for a fair assessment of CS. 155
Shown below is the coupled system of non-linear differential equations which describe the treatment 156 regimen involving two antimicrobials. We carefully simulate solutions using Matlab. The system is stiff 157 for some parameter values, and we utilize a stiff solver in such cases. 158 159
Mathematical Modeling 160
For all antibiotics, 161 In silico assessment of two drug cycling. 220
We simulate treatment with two antimicrobials exhibiting varying PD parameters and encompassing 221 both bacteriostatic (S) and bactericidal (C) drug types (See Table 1 and Materials & Methods). We 222 consider both daily cycling and three-day cycling of each antibiotic. We define the time to fixation, Tfix, 223 as the time between first application of drug 1 and the time at which the double resistant strain exceeds 224 0.9 N0. The simulation results are summarized in Table 1 applied antibiotics occurs rapidly, Tfi x ranging between 67 hours and 115 hours. This occurred despite the 235 increased susceptibility imposed by CS theory. The fixation of doubly resistant strains is seen to be 236 invariable, although it takes 50% longer when drugs are cycled every three days than when cycling daily. 237
The use of drugs with smaller Hill coefficients (β) leads to a 25% delay in fixation. Less significant are the 238 differences between the various combinations of static and cidal drugs. For drugs with small Hill 239 coefficients however, there is a 5% delay in fixation when one static drug is used and a further 5% delay 240 when both cycled drugs are bacteriostatic. 241 
248 For moderate to high dosing schemes (~ 10x MIC of sensitive cells), for drugs having large β, doubly 249 resistant mutants fixate rapidly, within four days of treatment initiation. This is not the case for drugs 250 with small β values with which resistance only emerges (and fixates) long after a traditional clinical 251 treatment regimen is completed, i.e. > 7-10 days. Tfi x also decreases when using two bactericidal (C / C) 252 drugs as compared to other combinations of cidal and static drugs (C / S or S / C). The best strategy of all 253 from our simulations is the use of two bacteriostatic drugs (S / S) with a low β, while cycling them every 254 three days. Under these conditions, no resistance is observed for any conceivable infection treatment 255 duration, which we interpret as meaning that such regimen with MCS guiding protocol may actually 256 inhibit the development of resistance. 257 258 Lastly, we note that significant short duration population spikes (> 10 5 CFU ml -1 ) occurred for some singly 259 resistant strains. 260
DISCUSSION 261
The emerging crisis that is pan antibiotic resistance, compounded by a dearth of new antibiotics in the 262 development pipeline 16 is necessitating new approaches to chemotherapy to minimize resistance emergence and dissemination. Many clinical treatment strategies have been proposed, ranging from 264 combinatorial therapy to antibiotic cycling incorporation in the treatment of everyday infections in 265 order to mitigate resistance emergence. Antibiotic cycling can be implemented either on the level of 266 individual patients or the institutional unit. Earlier modeling studies of unit cycling cast doubts on the 267 utility of this strategy 17 and results of hospital trials have been mixed. 268
The MCS approach is an exciting treatment option but multiple cycle testing with clinically relevant 269 PK/PD consideration has not been explored. Our mathematical model allows us to do precisely this, Intragenic suppression is limited by the smaller number of mutations that can lead to an MCS phenotype 279 for a related antibiotic while epistatic suppression is more dependent on an underlying genetic diversity. 280
These are also discussed in 7 and the observed saddlepoint in their published evolutionary landscape 281 points to potential treatment failure; evolutionary unpredictability as such is not considered herein. 282
These only serve to bolster the importance of our comprehensive pharmacodynamic study. 283 284 Pharmacodynamic properties of antibiotics are broadly delineated as bacteriostatic or bactericidal for 285 ease of pharmacological understanding. Most bacteriostatic drugs are weakly -cidal and while 286 bactericidal drugs are often preferred to bacteriostatic drugs, in immunocompetent patients, there is no 287 advantage in using the former. From our simulations, it appears that when exploiting MCS, the 288 bacteriostatic drugs are superior to their -cidal counterparts, as they inhibit resistance development. To 289 our knowledge, this is the first report or observation of such, emerging albeit from an in silico study. 290
As presented in the Results section, we observe the rapid fixation of resistance in all cases of low drug 291 concentration exposure, underlining the importance of adequate dosage. The large population sizes 292 commonly associated with infections, also considered in our study, would require an immunocompetent 293 host (patient) to clear. At first glance, our model lacks both innate and adaptive immunity (approached 294 in 18 ) but the innate immunity is implicit in form of resource concentration limitation on population size. 295
From the estimates of Tfix, the single factor most significant in the early fixation of multiple resistance 296 using this MCS protocol is the cycling period (cv 67 h vs. 110 h for one day cycling and three day cycling 297 respectively). Following this is the effect of the Hill coefficient, β, on Tfix which, in line with, 19 challenges 298 the idea that increased clearance rates minimize the selection and fixation of resistant isolates. The 299 increased selective pressure imposed by higher order bactericidal drugs leads to a more rapid fixation of 300 resistance in the population. Our model explains this from a nutrient competition perspective; as 301 antibiotic 2 is being applied, the killing of the sensitive cells and those resistant to antibiotic 1, results 302 effectively in reducing the total population density and thus competition is relaxed. 303 This is also true for the other antibiotics and evolution of doubly resistant mutants is facilitated by the 304 large population sizes being acted upon by the imposed (conservative) mutation rate in our model (See 305 In vivo, the immune system works hand in hand with antibiotics to clear the infection. In some of our 319 simulations, the single and double mutants remain at low enough densities to be easily cleared by 320 circulating immune cells. However, when fixation of double mutants occurs within a few days, the 321 likelihood of treatment failure would by definition, increase. Even in cases where fixation does occur, 322 the immune system, unaffected by AMR state may still clear. As such our model only serves as a 323 cautionary tale; heterogeneity in immunity and an immunocompromised state could exacerbate the 324 likelihood of treatment failure, as would antimicrobial heteroresistance, inoculum effects and high 325 frequency of AMR bacteria in the original infection. 326
In addition, horizontal gene transfer confounds the model's predictability as the rate of plasmid-327 mediated resistance transmission, especially conjugable plasmids, is considerably higher than the 328 replication dependent vertical propagation of point mutations. We do not consider plasmid-based 329 transmission of antimicrobial resistance genes and neither do we include any resistant mutants initially, 330 only considering de novo mutations conferring resistance. These mutations we assume occur 331 independently of one another. Under continuous antibiotic exposure, selection drives the system 332 towards a fitness maximum through resistance compensation which is favored over reversion 12 The modeling framework we present in this manuscript treats two drug cycling but has already been 341 extended to three drug cycling in anticipation of triplet combinations that may be identified in due 342 course. Before clinical deployment however, the utility of MCS must be explored experimentally, 343
rationalized physiologically, and further tested for generality. Mathematical models of this sort will play a crucial role in establishing the applicability and suggesting modifications to this and other proposed 345 treatment regimen. 346 347
